{
  "guideline": {
    "id": "PA166176623",
    "name": "Annotation of CPIC Guideline for oxcarbazepine and HLA-B",
    "source": "CPIC",
    "version": 18,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166176623",
    "relatedChemicals": [
      {
        "id": "PA450732",
        "name": "oxcarbazepine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166298338",
      "name": "Recommendation PA166298338",
      "population": "OXC naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450732",
          "name": "oxcarbazepine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060940,
        "html": "<p>If patient is oxcarbazepine-naïve, do not use oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.</p>\n"
      },
      "implications": [
        "HLA-B: Greater risk of oxcarbazepine-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298339",
      "name": "Recommendation PA166298339",
      "population": "OXC use >3 mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450732",
          "name": "oxcarbazepine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060941,
        "html": "<p>Use oxcarbazepine per standard dosing guidelines.</p>\n"
      },
      "implications": [
        "HLA-B: Normal risk of oxcarbazepine-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298340",
      "name": "Recommendation PA166298340",
      "population": "OXC use >3 mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450732",
          "name": "oxcarbazepine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060942,
        "html": "<p>The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of oxcarbazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.</p>\n"
      },
      "implications": [
        "HLA-B: Greater risk of oxcarbazepine-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298337",
      "name": "Recommendation PA166298337",
      "population": "OXC naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450732",
          "name": "oxcarbazepine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060939,
        "html": "<p>Use oxcarbazepine per standard dosing guidelines.</p>\n"
      },
      "implications": [
        "HLA-B: Normal risk of oxcarbazepine-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "29392710",
      "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.",
      "authors": [
        "Phillips Elizabeth J",
        "Sukasem Chonlaphat",
        "Whirl-Carrillo Michelle",
        "Müller Daniel J",
        "Dunnenberger Henry M",
        "Chantratita Wasun",
        "Goldspiel Barry",
        "Chen Yuan-Tsong",
        "Carleton Bruce C",
        "George Alfred L",
        "Mushiroda Taisei",
        "Klein Teri",
        "Gammal Roseann S",
        "Pirmohamed Munir"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2018,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847474"
    }
  ],
  "version": "2024-02-29-20-19"
}